Forma Therapeutics Raises $100 Million in Series D Financing & Can we do science without animal testing? @ Major Pros and Cons of Animal Testing That You Should Know & Why Animals Are Needed in Research & Animal Research Laboratory @ A day in the life of an animal technologist & Math is the hidden secret to understanding the world | Roger Antonsen @ 1. Introduction to Human Behavioral Biology @ ´´Various mutant strains of mice have been created by a number of methods.´´While mice are by far the most widely used animals in biomedical research, recent studies have highlighted their limitations.[37] Regarding experiments on mice, some researchers have complained that “years and billions of dollars have been wasted following false leads” as a result of a preoccupation with the use of these animals in studies.[37] An article in The Scientist notes, “The difficulties associated with using animal models for human disease result from the metabolic, anatomic, and cellular differences between humans and other creatures, but the problems go even deeper than that” including issues with the design and execution of the tests themselves.[40] Researchers have also noted that many studies involving mice are poorly designed, leading to questionable findings.[40][42][43]´´ @ OTHER VERY IMPORTANT INFORMATION LIKE YOUTUBE VIDEOS (LINKS) AND IMAGES

Do the downloads!! Share!! The diffusion of very important information and knowledge is essential for the world progress always!! Thanks!!

  • – > Mestrado – Dissertation – Tabelas, Figuras e Gráficos – Tables, Figures and Graphics – ´´My´´ Dissertation @ #Innovation #energy #life #health #Countries #Time #Researches #Reference #Graphics #Ages #Age #Mice #People #Person #Mouse #Genetics #PersonalizedMedicine #Diagnosis #Prognosis #Treatment #Disease #UnknownDiseases #Future #VeryEfficientDrugs #VeryEfficientVaccines #VeryEfficientTherapeuticalSubstances #Tests #Laboratories #Investments #Details #HumanLongevity #DNA #Cell #Memory #Physiology #Nanomedicine #Nanotechnology #Biochemistry #NewMedicalDevices #GeneticEngineering #Internet #History #Science #World

Pathol Res Pract. 2012 Jul 15;208(7):377-81. doi: 10.1016/j.prp.2012.04.006. Epub 2012 Jun 8.

The influence of physical activity in the progression of experimental lung cancer in mice

Renato Batista Paceli 1Rodrigo Nunes CalCarlos Henrique Ferreira dos SantosJosé Antonio CordeiroCassiano Merussi NeivaKazuo Kawano NagaminePatrícia Maluf Cury


Impact_Fator-wise_Top100Science_Journals

GRUPO_AF1 – GROUP AFA1 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO AFAN 1 – GROUP AFAN1 – Anaerobic Physical Activity – Atividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO_AF2 – GROUP AFA2 – Aerobic Physical Activity – Atividade Física Aeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

GRUPO AFAN 2 – GROUP AFAN 2 – Anaerobic Physical Activity – Atividade Física Anaeróbia – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

Slides – mestrado – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

CARCINÓGENO DMBA EM MODELOS EXPERIMENTAIS

DMBA CARCINOGEN IN EXPERIMENTAL MODELS

Avaliação da influência da atividade física aeróbia e anaeróbia na progressão do câncer de pulmão experimental – Summary – Resumo – ´´My´´ Dissertation – Faculty of Medicine of Sao Jose do Rio Preto

https://pubmed.ncbi.nlm.nih.gov/22683274/

Abstract

Lung cancer is one of the most incident neoplasms in the world, representing the main cause of mortality for cancer. Many epidemiologic studies have suggested that physical activity may reduce the risk of lung cancer, other works evaluate the effectiveness of the use of the physical activity in the suppression, remission and reduction of the recurrence of tumors. The aim of this study was to evaluate the effects of aerobic and anaerobic physical activity in the development and the progression of lung cancer. Lung tumors were induced with a dose of 3mg of urethane/kg, in 67 male Balb – C type mice, divided in three groups: group 1_24 mice treated with urethane and without physical activity; group 2_25 mice with urethane and subjected to aerobic swimming free exercise; group 3_18 mice with urethane, subjected to anaerobic swimming exercise with gradual loading 5-20% of body weight. All the animals were sacrificed after 20 weeks, and lung lesions were analyzed. The median number of lesions (nodules and hyperplasia) was 3.0 for group 1, 2.0 for group 2 and 1.5-3 (p=0.052). When comparing only the presence or absence of lesion, there was a decrease in the number of lesions in group 3 as compared with group 1 (p=0.03) but not in relation to group 2. There were no metastases or other changes in other organs. The anaerobic physical activity, but not aerobic, diminishes the incidence of experimental lung tumors.

https://biotechbrothers.com/2019/12/22/forma-therapeutics-raises-100-million-in-series-d-financing/?fbclid=IwAR32wdNlqGJdsU2elHAGu4eLPoCeAtlew1HNhbPJj_PruXudbAWL-YeTnEE

BIOTECH BROTHERS®

SearchSearch

BIOTECH BROTHERS®

Join Biotech Brothers

Purchase Ebook

Ever wonder how to break into the biotech industry? This is the booklet you need!

$2.99BIOPHARMABIOPHARMACEUTICALSBIOTECHBIOTECH BILLIONAIREBIOTECH HUBBREAKING IN BIOTECHCAPITALFORMAFORMA THERAPEUTICSPHARMAPHASE 1/2PHASE IPKRSICKLE CELL DISEASESTART UPSTARTUPSTHERAPEUTICSVENTURE CAPITALIST

Forma Therapeutics Raises $100 Million in Series D Financing

BY BIOTECHBROTHERSDECEMBER 22, 2019COMMENTS 0

FORMA Therapeutics, a biopharmaceutical company headquartered in Massachusetts, just sent out a press release announcing that the company raised $100 Million (Yes, a hundred million :O). A monstrous round in Series D Financing will fuel the development of their therapy FT-4202 and FT-7051 that is treating patients suffering from rare blood disorders.

FORMA’s FT4202 may potentially play a critical role for being the next therapy for sickle cell. By targeting the mechanism of action that often leads to the development of blood disorders in patients, one can reverse and prevent the development of sickle cell disease. Patients who suffer from this disease tend to have a deficiency of PKR. FORMA’s investigational drug addresses this issue by being an activator for pyruvate kinase RNA (PKR). The activation leads to PKR activation and the binding of hemoglobin to oxygen for these patients.

In a research paper, Allosteric inhibitors of pyruvate Kinase, pyruvate kinase activators can be used potentially as a pharmaceutical treatment for patients with PK deficiency. Because kinase influences the metabolic process and glycolytic pathway, 2,3-diphosphoglycerate, a protein critical in letting hemoglobin to have the affinity it needs to bind with oxygen.

Most drugs that are produced by pharmaceuticals and biotechnology companies try to treat the symptoms of the disease. By reversing and preventing the development of this disease, an activator of PKR can potentially give better results for patients with rare hematologic disorders.

We are no longer creating traditional drugs that just treat the symptoms of a patient, BUT RATHER we are now looking at the underlying cause of a disease.

Don’t forget to subscribe to Biotech Brothers!AdvertisementsREPORT THIS ADAdvertisementsREPORT THIS AD

SHARE THIS:

TAGSFEATURED

ABOUT BIOTECHBROTHERS

A biotechnology and sci fi nerd, that enjoys writing about new innovations within the science world and industry.biotechbrothers.wordpress.com

0 COMMENTS ON “FORMA THERAPEUTICS RAISES $100 MILLION IN SERIES D FINANCING”

LEAVE A REPLY

Gravatar

ciencia100: You are commenting using your WordPress.com account. ( Log Out /  Change )

 Notify me of new comments via email.

 Notify me of new posts via email.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Post navigation

PREVIOUS POST

Like our Facebook Page!

Ebook: Breaking into Biotech

Purchase Ebook

Ever wonder how to break into the biotech industry? This is the booklet you need!

$2.99

KNOWLEDGE EMPOWERS

Search for:

Follow Us

Related

Novartis Acquires The Medicines Company for $9.7 Billion

Novartis Acquires The Medicines Company for $9.7 Billion

An Enzyme May be the Key to Stopping Parkinson's

An Enzyme May be the Key to Stopping Parkinson’s

Vertex Shells Out $950 Million for Semma Therapeutics

Vertex Shells Out $950 Million for Semma Therapeutics

Vertex Pharmaceuticals has a Thing for Genetic Engineering Start Ups

Vertex Pharmaceuticals has a Thing for Genetic Engineering Start Ups

Powered by WordPress.com.

9 Comments

  1. Hey would you mind stating which blog platform you’re using? I’m going to start my own blog in the near future but I’m having a hard time selecting between BlogEngine/Wordpress/B2evolution and Drupal. The reason I ask is because your layout seems different then most blogs and I’m looking for something completely unique. P.S Sorry for being off-topic but I had to ask!

    Like

  2. Hеy! I’m at ԝork surfing around your blog from my new
    apрⅼe iphone! Jᥙst wanted to sаy I lⲟve reading your blog
    and look forward to all your posts! Carry on the outstanding work!

    Like

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s